Employees are willing to change jobs to receive better coverage for specialty medications.
Nearly half of Americans have experienced challenges getting specialty medications, according to the findings of a recent survey by The Harris Poll on behalf of RxBenefits.
Many respondents (24%) reported the top challenge experienced was the overall cost of the medication being too high. Another barrier was the medication not being covered by an employer-provided health plan (16%).
“Specialty drug utilization continues to increase, and is showing no signs of slowing down,” Bryan Statham, chief executive officer of RxBenefits, said in a press release. “In fact, specialty medication costs accounted for over 50% of the total pharmacy spend incurred in 2020. While specialty carve-out has often been touted as an effective method to contain costs, the approach is not effective for employees and can actually cause severe member and service disruption.”
Statham suggested employers go beyond providing a paycheck to attract and retain talent. In fact, a rich benefits package while keeping costs low could lead to a healthier bottom line and more satisfied workforce.
Findings of the survey also revealed Americans aged 18-44 years old were more likely than those at least 45 years old to say they would switch jobs to get coverage if their employer-provided benefits did not cover the coast of their, or a family member’s, specialty medications (19% vs 5%). What’s more those aged 18-44 years old were more likely than those at least 55 years old to say they would involve their company’s human resources department to gain coverage (21% vs 10%).
Still, 73% of Americans surveyed were currently covered by an employer-provided health benefits plan with prescription drug coverage. And 80% said it was important their current or future employer-provided health benefits plan will cover the cost of specialty medications for them or their family.
“The results of this survey further showcase just how important medication coverage is to today’s consumers,” Mark Campbell, Pharm.D., vice president of clinical solutions at RxBenefits, said in the press release. “And while the benefits landscape can certainly be complicated, employers need an advocate that watches out for their financial interests as well as the best health of their employees — someone that helps them understand when something is right and when it’s not.”
The online survey was conducted within the U.S. between June 24-28, 2021, and included more than 2,000 adults at least 18 years old.
Medicaid Cuts Remain Center Stage as Experts Address Industry Challenges
March 28th 2025In a recent conversation with Jennifer McGuigan Babcock, senior vice president for Medicaid policy at the Association for Community Affiliated Plans (ACAP), and Gabe Scott, a partner at K&L Gates Health Care Group, the two discussed efforts to protect Medicaid’s role in the healthcare system and the consequences of the budget cuts announced in February.
Read More
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
FDA Approves First Drug for Excess Hunger in Prader-Willi Syndrome
March 27th 2025Vykat XR will be available in April to treat the intense hunger that is a hallmark of the rare genetic disease Prader-Willi syndrome. The price is based on a patient’s weight, and the average patient in the clinical trials would have had an average annual cost of $466,200 for the first year.
Read More